mozavaptan has been researched along with conivaptan in 10 studies
| Studies (mozavaptan) | Trials (mozavaptan) | Recent Studies (post-2010) (mozavaptan) | Studies (conivaptan) | Trials (conivaptan) | Recent Studies (post-2010) (conivaptan) |
|---|---|---|---|---|---|
| 165 | 8 | 24 | 188 | 17 | 64 |
| Protein | Taxonomy | mozavaptan (IC50) | conivaptan (IC50) |
|---|---|---|---|
| Vasopressin V2 receptor | Homo sapiens (human) | 0.011 | |
| Vasopressin V1a receptor | Homo sapiens (human) | 0.003 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishii, N; Kusayama, T; Saito, M; Sugimoto, T; Tahara, A; Tanaka, A; Tomura, Y; Tsukada, J; Uchida, W; Wada, K; Yatsu, T | 1 |
| Ishii, N; Kusayama, T; Tahara, A; Tanaka, A; Tomura, Y; Tsukada, J; Uchida, W; Wada, K; Yatsu, T | 1 |
| Ezure, Y; Fukaya, AY; Hasegaw, H; Koike, K; Kurasawa, T; Matsukawa, H; Naito, A; Naito, K; Oguma, T; Ohtake, Y; Shigenobu, K; Tanaka, H; Tsuriya, Y | 1 |
| Ferguson, JW; Hayes, PC; Newby, DE; Therapondos, G | 1 |
| Chen, RH; Demarest, KT; Ericson, E; Gunnet, J; Look, R; Murray, WV; Rybczynski, PJ; Urbanski, MJ; Zhang, X | 1 |
| Gross, P; Herbrig, K; Palm, C; Pistrosch, F | 1 |
| Ginès, P; Guevara, M; Martín-Llahí, M | 1 |
| Villabona, C | 1 |
| Dabrowska, MD; Krysiak, R; Okopień, B | 1 |
| Iwao, H; Izumi, Y; Miura, K | 1 |
6 review(s) available for mozavaptan and conivaptan
| Article | Year |
|---|---|
Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Controlled Clinical Trials as Topic; Diuretics; Heart Failure; Homeostasis; Humans; Inappropriate ADH Syndrome; Liver Cirrhosis; Models, Animal; Morpholines; Piperidines; Pyrroles; Quinolones; Rats; Spiro Compounds; Vasopressins | 2003 |
Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.
Topics: Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Humans; Hyponatremia; Inappropriate ADH Syndrome; Morpholines; Pyrroles; Randomized Controlled Trials as Topic; Spiro Compounds; Tolvaptan; Vasopressins | 2006 |
Hyponatremia in cirrhosis: clinical features and management.
Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Brain; Clinical Trials, Phase II as Topic; Controlled Clinical Trials as Topic; Creatinine; Forecasting; Hepatic Encephalopathy; Humans; Hyponatremia; Liver Cirrhosis; Liver Transplantation; Prognosis; Research; Risk Factors; Sodium; Time Factors; Treatment Outcome | 2006 |
[Vasopressin receptor antagonists: the vaptans].
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzamides; Benzazepines; Calcium Signaling; Clinical Trials as Topic; Cyclic AMP; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Kidney Tubules, Collecting; Liver Cirrhosis; Morpholines; Multicenter Studies as Topic; Neoplasms; Pituitary Gland, Anterior; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Second Messenger Systems; Spiro Compounds; Tolvaptan; Vasopressins | 2010 |
[Hyponatremic hypervolemia in heart failure--the hot spot for vasopressin receptor antagonists?].
Topics: Antidiuretic Hormone Receptor Antagonists; Benzamides; Benzazepines; Diuretics; Heart Failure; Humans; Hyponatremia; Hypovolemia; Morpholines; Pyrroles; Spiro Compounds; Tolvaptan | 2012 |
Therapeutic potential of vasopressin-receptor antagonists in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Benzazepines; Body Water; Clinical Trials as Topic; Disease Models, Animal; Heart Failure; Homeostasis; Humans; Hyponatremia; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan; Ventricular Remodeling | 2014 |
4 other study(ies) available for mozavaptan and conivaptan
| Article | Year |
|---|---|
Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
Topics: Animals; Benzazepines; Binding, Competitive; Calcium; CHO Cells; Cricetinae; Cyclic AMP; Humans; Indoles; Morpholines; Piperidines; Pyrrolidines; Quinolones; Receptors, Vasopressin; Spiro Compounds; Transfection; Tritium | 1998 |
Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte.
Topics: Analysis of Variance; Animals; Animals, Newborn; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Calcium; Calcium-Calmodulin-Dependent Protein Kinases; Cells, Cultured; Leucine; Myocardium; Piperidines; Protein Biosynthesis; Quinolones; Rats; Rats, Wistar; Receptors, Vasopressin; Stimulation, Chemical; Thymidine | 1998 |
Pharmacological profile of VP-343, a novel selective vasopressin V2 receptor antagonist, in rats.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Pressure; Diuretics; Electrolytes; Female; Furosemide; Male; Mice; Mice, Inbred ICR; Pyrroles; Quinoxalines; Rats; Rats, Brattleboro; Rats, Sprague-Dawley; Receptors, Vasopressin; Urodynamics | 2000 |
2,5-disubstituted 3,4-dihydro-2H-benzo[b][1,4]thiazepines as potent and selective V2 arginine vasopressin receptor antagonists.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Dibenzothiazepines; Diuresis; Drug Design; Kinetics; Male; Pyrroles; Rats; Structure-Activity Relationship | 2003 |